Preferred Label : belzutifan;

MeSH hyponym : MK6482; PT2977;

UNII : 7K28NB895L;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/en/medicines/human/EPAR/welireg
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, oral
belzutifan
belzutifan
belzutifan
antineoplastic agents
antineoplastic agents
HIF-2alpha Inhibitor
HIF-2alpha Inhibitor
risk management
product surveillance, postmarketing
clear cell renal cell carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Refractory Clear Cell Renal Cell Carcinoma
adult
von Hippel-Lindau disease
Central Nervous System Hemangioblastoma
carcinoma, renal cell
Pancreatic Neuroendocrine Tumor
Unresectable Pancreatic Neuroendocrine Tumor
EPAS1 protein, human
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://ansm.sante.fr/tableau-marr/belzutifan
2025
false
false
false
France
French
risk management
belzutifan
belzutifan
antineoplastic agents
pregnancy
guidelines for drug use
patient education handout

---
https://www.has-sante.fr/jcms/p_3633406/fr/welireg-belzutifan-maladie-de-von-hippel-lindau
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
belzutifan
adult
guidelines for drug use
administration, oral
antineoplastic agents
evaluation of the transparency committee
von Hippel-Lindau disease
belzutifan

---
https://www.cadth.ca/fr/belzutifan
2023
false
false
false
Canada
French
English
drug evaluation
canada
belzutifan
belzutifan
von Hippel-Lindau disease

---
Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.